nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—SST—pancreatic cancer	0.702	1	CbGaD
Cysteamine—SST—ventral pancreatic duct—pancreatic cancer	0.0287	0.251	CbGeAlD
Cysteamine—SST—hepatic artery—pancreatic cancer	0.0279	0.245	CbGeAlD
Cysteamine—SST—portal vein—pancreatic cancer	0.0242	0.212	CbGeAlD
Cysteamine—MPO—superior mesenteric artery—pancreatic cancer	0.0214	0.187	CbGeAlD
Cysteamine—SST—gall bladder—pancreatic cancer	0.00416	0.0365	CbGeAlD
Cysteamine—SST—islet of Langerhans—pancreatic cancer	0.00273	0.0239	CbGeAlD
Cysteamine—SST—pancreas—pancreatic cancer	0.00192	0.0168	CbGeAlD
Cysteamine—SST—digestive system—pancreatic cancer	0.00164	0.0144	CbGeAlD
Cysteamine—MPO—pancreas—pancreatic cancer	0.000772	0.00677	CbGeAlD
Cysteamine—MPO—digestive system—pancreatic cancer	0.000659	0.00578	CbGeAlD
Cysteamine—SST—GPCR ligand binding—GCG—pancreatic cancer	0.000245	0.00214	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—CNR1—pancreatic cancer	0.000243	0.00212	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PPY—pancreatic cancer	0.000242	0.00211	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—CCKBR—pancreatic cancer	0.000239	0.00209	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—SSTR2—pancreatic cancer	0.000237	0.00208	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CASP3—pancreatic cancer	0.000235	0.00205	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—GCG—pancreatic cancer	0.000235	0.00205	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—AGTR1—pancreatic cancer	0.000233	0.00204	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—CCKBR—pancreatic cancer	0.000229	0.002	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—GAST—pancreatic cancer	0.000226	0.00198	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CTNNB1—pancreatic cancer	0.000226	0.00198	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—AGTR1—pancreatic cancer	0.000224	0.00196	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—GAST—pancreatic cancer	0.000217	0.0019	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—TNF—pancreatic cancer	0.000215	0.00188	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—SCT—pancreatic cancer	0.000215	0.00188	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.000209	0.00183	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—SCT—pancreatic cancer	0.000206	0.0018	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—GAST—pancreatic cancer	0.000206	0.0018	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—CCK—pancreatic cancer	0.000205	0.00179	CbGpPWpGaD
Cysteamine—NPY2R—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.000201	0.00176	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—CNR2—pancreatic cancer	0.0002	0.00175	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—GLP1R—pancreatic cancer	0.0002	0.00175	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	0.000199	0.00174	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—GAST—pancreatic cancer	0.000197	0.00172	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—CCK—pancreatic cancer	0.000196	0.00172	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000196	0.00172	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—PIK3CA—pancreatic cancer	0.000196	0.00171	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—SCT—pancreatic cancer	0.000195	0.0017	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—CNR2—pancreatic cancer	0.000191	0.00167	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000191	0.00167	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000188	0.00165	CbGpPWpGaD
Cysteamine—Abdominal pain—Erlotinib—pancreatic cancer	0.000187	0.00269	CcSEcCtD
Cysteamine—Body temperature increased—Erlotinib—pancreatic cancer	0.000187	0.00269	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—SCT—pancreatic cancer	0.000187	0.00163	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PRLHR—pancreatic cancer	0.000186	0.00163	CbGpPWpGaD
Cysteamine—Anaemia—Gemcitabine—pancreatic cancer	0.000186	0.00267	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CCK—pancreatic cancer	0.000186	0.00163	CbGpPWpGaD
Cysteamine—Leukopenia—Irinotecan—pancreatic cancer	0.000185	0.00266	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Epirubicin—pancreatic cancer	0.000184	0.00264	CcSEcCtD
Cysteamine—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000183	0.00263	CcSEcCtD
Cysteamine—Anaemia—Fluorouracil—pancreatic cancer	0.000183	0.00263	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CNR2—pancreatic cancer	0.000181	0.00158	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—GLP1R—pancreatic cancer	0.000181	0.00158	CbGpPWpGaD
Cysteamine—Dyspepsia—Sunitinib—pancreatic cancer	0.00018	0.00259	CcSEcCtD
Cysteamine—Leukopenia—Gemcitabine—pancreatic cancer	0.00018	0.00259	CcSEcCtD
Cysteamine—Renal failure—Docetaxel—pancreatic cancer	0.00018	0.00258	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PRLHR—pancreatic cancer	0.000179	0.00156	CbGpPWpGaD
Cysteamine—Hypertension—Irinotecan—pancreatic cancer	0.000178	0.00256	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CCKAR—pancreatic cancer	0.000178	0.00156	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—CCK—pancreatic cancer	0.000178	0.00156	CbGpPWpGaD
Cysteamine—Decreased appetite—Sunitinib—pancreatic cancer	0.000178	0.00256	CcSEcCtD
Cysteamine—Eye pain—Epirubicin—pancreatic cancer	0.000177	0.00255	CcSEcCtD
Cysteamine—Leukopenia—Fluorouracil—pancreatic cancer	0.000177	0.00255	CcSEcCtD
Cysteamine—Mental disability—Doxorubicin—pancreatic cancer	0.000177	0.00254	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000177	0.00254	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—IAPP—pancreatic cancer	0.000177	0.00155	CbGpPWpGaD
Cysteamine—SST—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.000177	0.00155	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—CDKN2A—pancreatic cancer	0.000177	0.00154	CbGpPWpGaD
Cysteamine—Fatigue—Sunitinib—pancreatic cancer	0.000176	0.00254	CcSEcCtD
Cysteamine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000176	0.00253	CcSEcCtD
Cysteamine—SST—Signaling Pathways—ACVR1B—pancreatic cancer	0.000175	0.00153	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ZNRF3—pancreatic cancer	0.000175	0.00153	CbGpPWpGaD
Cysteamine—Constipation—Sunitinib—pancreatic cancer	0.000175	0.00252	CcSEcCtD
Cysteamine—Discomfort—Irinotecan—pancreatic cancer	0.000174	0.0025	CcSEcCtD
Cysteamine—Hypertension—Gemcitabine—pancreatic cancer	0.000174	0.0025	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CNR2—pancreatic cancer	0.000174	0.00152	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—GLP1R—pancreatic cancer	0.000174	0.00152	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—PTEN—pancreatic cancer	0.000173	0.00151	CbGpPWpGaD
Cysteamine—Asthenia—Tamoxifen—pancreatic cancer	0.000171	0.00246	CcSEcCtD
Cysteamine—Convulsion—Fluorouracil—pancreatic cancer	0.000171	0.00246	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CCKAR—pancreatic cancer	0.000171	0.00149	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—TNF—pancreatic cancer	0.000171	0.00149	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—pancreatic cancer	0.00017	0.00245	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00017	0.00244	CcSEcCtD
Cysteamine—Confusional state—Irinotecan—pancreatic cancer	0.00017	0.00244	CcSEcCtD
Cysteamine—Asthenia—Erlotinib—pancreatic cancer	0.00017	0.00244	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—PTHLH—pancreatic cancer	0.00017	0.00148	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—IAPP—pancreatic cancer	0.000169	0.00148	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.000169	0.00148	CbGpPWpGaD
Cysteamine—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000169	0.00243	CcSEcCtD
Cysteamine—Discomfort—Gemcitabine—pancreatic cancer	0.000169	0.00243	CcSEcCtD
Cysteamine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000169	0.00242	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—ZNRF3—pancreatic cancer	0.000168	0.00147	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ACVR1B—pancreatic cancer	0.000168	0.00147	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000167	0.00241	CcSEcCtD
Cysteamine—Discomfort—Fluorouracil—pancreatic cancer	0.000166	0.00239	CcSEcCtD
Cysteamine—MPO—Vitamin B12 Metabolism—TNF—pancreatic cancer	0.000166	0.00145	CbGpPWpGaD
Cysteamine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000165	0.00238	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—PTGS2—pancreatic cancer	0.000165	0.00144	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000164	0.00236	CcSEcCtD
Cysteamine—Eye pain—Doxorubicin—pancreatic cancer	0.000164	0.00236	CcSEcCtD
Cysteamine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000164	0.00235	CcSEcCtD
Cysteamine—Lethargy—Epirubicin—pancreatic cancer	0.000163	0.00235	CcSEcCtD
Cysteamine—Confusional state—Fluorouracil—pancreatic cancer	0.000163	0.00234	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000163	0.00142	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—SHH—pancreatic cancer	0.000163	0.00142	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000162	0.00233	CcSEcCtD
Cysteamine—Body temperature increased—Sunitinib—pancreatic cancer	0.000162	0.00233	CcSEcCtD
Cysteamine—Abdominal pain—Sunitinib—pancreatic cancer	0.000162	0.00233	CcSEcCtD
Cysteamine—Diarrhoea—Erlotinib—pancreatic cancer	0.000162	0.00232	CcSEcCtD
Cysteamine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000162	0.00232	CcSEcCtD
Cysteamine—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000161	0.00232	CcSEcCtD
Cysteamine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000161	0.00231	CcSEcCtD
Cysteamine—Urethral disorder—Docetaxel—pancreatic cancer	0.000161	0.00231	CcSEcCtD
Cysteamine—Anorexia—Irinotecan—pancreatic cancer	0.000161	0.00231	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—IAPP—pancreatic cancer	0.00016	0.0014	CbGpPWpGaD
Cysteamine—Pain in extremity—Epirubicin—pancreatic cancer	0.00016	0.0023	CcSEcCtD
Cysteamine—Skin disorder—Gemcitabine—pancreatic cancer	0.00016	0.00229	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS2—pancreatic cancer	0.000159	0.00139	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—SSTR3—pancreatic cancer	0.000158	0.00139	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—DTX1—pancreatic cancer	0.000158	0.00139	CbGpPWpGaD
Cysteamine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000158	0.00228	CcSEcCtD
Cysteamine—Dizziness—Tamoxifen—pancreatic cancer	0.000158	0.00227	CcSEcCtD
Cysteamine—Affect lability—Epirubicin—pancreatic cancer	0.000157	0.00226	CcSEcCtD
Cysteamine—Anorexia—Gemcitabine—pancreatic cancer	0.000157	0.00225	CcSEcCtD
Cysteamine—Dizziness—Erlotinib—pancreatic cancer	0.000156	0.00225	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—SHH—pancreatic cancer	0.000156	0.00136	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PTHLH—pancreatic cancer	0.000154	0.00135	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PTCH1—pancreatic cancer	0.000154	0.00135	CbGpPWpGaD
Cysteamine—Anorexia—Fluorouracil—pancreatic cancer	0.000154	0.00221	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—IAPP—pancreatic cancer	0.000154	0.00135	CbGpPWpGaD
Cysteamine—Vomiting—Tamoxifen—pancreatic cancer	0.000152	0.00218	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—DTX1—pancreatic cancer	0.000152	0.00133	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—SSTR1—pancreatic cancer	0.000152	0.00133	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SSTR3—pancreatic cancer	0.000152	0.00133	CbGpPWpGaD
Cysteamine—Mood swings—Epirubicin—pancreatic cancer	0.000152	0.00218	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—pancreatic cancer	0.000151	0.00217	CcSEcCtD
Cysteamine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000151	0.00217	CcSEcCtD
Cysteamine—Rash—Tamoxifen—pancreatic cancer	0.000151	0.00217	CcSEcCtD
Cysteamine—Dermatitis—Tamoxifen—pancreatic cancer	0.000151	0.00216	CcSEcCtD
Cysteamine—Ataxia—Epirubicin—pancreatic cancer	0.00015	0.00216	CcSEcCtD
Cysteamine—Vomiting—Erlotinib—pancreatic cancer	0.00015	0.00216	CcSEcCtD
Cysteamine—Somnolence—Irinotecan—pancreatic cancer	0.00015	0.00215	CcSEcCtD
Cysteamine—Headache—Tamoxifen—pancreatic cancer	0.00015	0.00215	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CCND1—pancreatic cancer	0.000149	0.00131	CbGpPWpGaD
Cysteamine—Rash—Erlotinib—pancreatic cancer	0.000149	0.00214	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PPY—pancreatic cancer	0.000149	0.0013	CbGpPWpGaD
Cysteamine—Dermatitis—Erlotinib—pancreatic cancer	0.000149	0.00214	CcSEcCtD
Cysteamine—Dehydration—Epirubicin—pancreatic cancer	0.000149	0.00214	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—SST—pancreatic cancer	0.000149	0.0013	CbGpPWpGaD
Cysteamine—Dyspepsia—Irinotecan—pancreatic cancer	0.000148	0.00213	CcSEcCtD
Cysteamine—Immune system disorder—Docetaxel—pancreatic cancer	0.000148	0.00213	CcSEcCtD
Cysteamine—Headache—Erlotinib—pancreatic cancer	0.000148	0.00213	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—pancreatic cancer	0.000148	0.00213	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—PTHLH—pancreatic cancer	0.000148	0.00129	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PTCH1—pancreatic cancer	0.000148	0.00129	CbGpPWpGaD
Cysteamine—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000148	0.00212	CcSEcCtD
Cysteamine—Asthenia—Sunitinib—pancreatic cancer	0.000147	0.00211	CcSEcCtD
Cysteamine—Decreased appetite—Irinotecan—pancreatic cancer	0.000147	0.00211	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SSTR2—pancreatic cancer	0.000146	0.00128	CbGpPWpGaD
Cysteamine—Somnolence—Gemcitabine—pancreatic cancer	0.000146	0.0021	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—pancreatic cancer	0.000146	0.00209	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SSTR1—pancreatic cancer	0.000146	0.00127	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000146	0.00209	CcSEcCtD
Cysteamine—Fatigue—Irinotecan—pancreatic cancer	0.000145	0.00209	CcSEcCtD
Cysteamine—Constipation—Irinotecan—pancreatic cancer	0.000144	0.00207	CcSEcCtD
Cysteamine—Mental disorder—Docetaxel—pancreatic cancer	0.000144	0.00207	CcSEcCtD
Cysteamine—Somnolence—Fluorouracil—pancreatic cancer	0.000144	0.00206	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—CNR1—pancreatic cancer	0.000143	0.00125	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PPY—pancreatic cancer	0.000143	0.00125	CbGpPWpGaD
Cysteamine—Erythema—Docetaxel—pancreatic cancer	0.000143	0.00205	CcSEcCtD
Cysteamine—Malnutrition—Docetaxel—pancreatic cancer	0.000143	0.00205	CcSEcCtD
Cysteamine—Decreased appetite—Gemcitabine—pancreatic cancer	0.000143	0.00205	CcSEcCtD
Cysteamine—Dyspepsia—Fluorouracil—pancreatic cancer	0.000142	0.00204	CcSEcCtD
Cysteamine—Nausea—Tamoxifen—pancreatic cancer	0.000142	0.00204	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000142	0.00204	CcSEcCtD
Cysteamine—Fatigue—Gemcitabine—pancreatic cancer	0.000142	0.00203	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CCKBR—pancreatic cancer	0.000141	0.00124	CbGpPWpGaD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.00014	0.00123	CbGpPWpGaD
Cysteamine—Constipation—Gemcitabine—pancreatic cancer	0.00014	0.00202	CcSEcCtD
Cysteamine—Nausea—Erlotinib—pancreatic cancer	0.00014	0.00202	CcSEcCtD
Cysteamine—Decreased appetite—Fluorouracil—pancreatic cancer	0.00014	0.00202	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—pancreatic cancer	0.00014	0.00201	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SSTR2—pancreatic cancer	0.00014	0.00123	CbGpPWpGaD
Cysteamine—Diarrhoea—Sunitinib—pancreatic cancer	0.00014	0.00201	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000139	0.002	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—pancreatic cancer	0.000139	0.002	CcSEcCtD
Cysteamine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000139	0.002	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—GCG—pancreatic cancer	0.000138	0.00121	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000138	0.00198	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—pancreatic cancer	0.000138	0.00198	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—CNR1—pancreatic cancer	0.000137	0.0012	CbGpPWpGaD
Cysteamine—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000137	0.00196	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CCKBR—pancreatic cancer	0.000135	0.00118	CbGpPWpGaD
Cysteamine—Dizziness—Sunitinib—pancreatic cancer	0.000135	0.00195	CcSEcCtD
Cysteamine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000135	0.00194	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TNF—pancreatic cancer	0.000135	0.00118	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—SST—pancreatic cancer	0.000135	0.00118	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000135	0.00118	CbGpPWpGaD
Cysteamine—Abdominal pain—Irinotecan—pancreatic cancer	0.000133	0.00192	CcSEcCtD
Cysteamine—Body temperature increased—Irinotecan—pancreatic cancer	0.000133	0.00192	CcSEcCtD
Cysteamine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000133	0.00191	CcSEcCtD
Cysteamine—SST—Signaling Pathways—DTX4—pancreatic cancer	0.000133	0.00116	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—GLI1—pancreatic cancer	0.000133	0.00116	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—GCG—pancreatic cancer	0.000133	0.00116	CbGpPWpGaD
Cysteamine—Anaemia—Docetaxel—pancreatic cancer	0.000132	0.0019	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000132	0.00115	CbGpPWpGaD
Cysteamine—Vomiting—Sunitinib—pancreatic cancer	0.00013	0.00187	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CNR1—pancreatic cancer	0.00013	0.00114	CbGpPWpGaD
Cysteamine—Body temperature increased—Gemcitabine—pancreatic cancer	0.00013	0.00187	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000129	0.00113	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—NRP1—pancreatic cancer	0.000129	0.00113	CbGpPWpGaD
Cysteamine—Rash—Sunitinib—pancreatic cancer	0.000129	0.00185	CcSEcCtD
Cysteamine—Dermatitis—Sunitinib—pancreatic cancer	0.000129	0.00185	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—NRAS—pancreatic cancer	0.000128	0.00112	CbGpPWpGaD
Cysteamine—Urticaria—Fluorouracil—pancreatic cancer	0.000128	0.00184	CcSEcCtD
Cysteamine—Headache—Sunitinib—pancreatic cancer	0.000128	0.00184	CcSEcCtD
Cysteamine—Leukopenia—Docetaxel—pancreatic cancer	0.000128	0.00184	CcSEcCtD
Cysteamine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000128	0.00183	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—DTX4—pancreatic cancer	0.000127	0.00111	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—GLI1—pancreatic cancer	0.000127	0.00111	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000126	0.00111	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—GCG—pancreatic cancer	0.000126	0.0011	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—CNR1—pancreatic cancer	0.000125	0.00109	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HEY2—pancreatic cancer	0.000124	0.00109	CbGpPWpGaD
Cysteamine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000124	0.00179	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—NRP1—pancreatic cancer	0.000124	0.00108	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000124	0.00108	CbGpPWpGaD
Cysteamine—Convulsion—Docetaxel—pancreatic cancer	0.000124	0.00178	CcSEcCtD
Cysteamine—Hypertension—Docetaxel—pancreatic cancer	0.000123	0.00177	CcSEcCtD
Cysteamine—Nausea—Sunitinib—pancreatic cancer	0.000122	0.00175	CcSEcCtD
Cysteamine—SST—Signaling Pathways—GAST—pancreatic cancer	0.000121	0.00106	CbGpPWpGaD
Cysteamine—Renal failure—Epirubicin—pancreatic cancer	0.000121	0.00174	CcSEcCtD
Cysteamine—Asthenia—Irinotecan—pancreatic cancer	0.000121	0.00174	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000121	0.00174	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—GCG—pancreatic cancer	0.00012	0.00105	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—AGTR1—pancreatic cancer	0.00012	0.00105	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—MYC—pancreatic cancer	0.00012	0.00105	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—TP53—pancreatic cancer	0.000119	0.00104	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HEY2—pancreatic cancer	0.000119	0.00104	CbGpPWpGaD
Cysteamine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000119	0.00171	CcSEcCtD
Cysteamine—Asthenia—Gemcitabine—pancreatic cancer	0.000118	0.00169	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—pancreatic cancer	0.000118	0.00103	CbGpPWpGaD
Cysteamine—Confusional state—Docetaxel—pancreatic cancer	0.000118	0.00169	CcSEcCtD
Cysteamine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000117	0.00167	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GAST—pancreatic cancer	0.000116	0.00102	CbGpPWpGaD
Cysteamine—Diarrhoea—Irinotecan—pancreatic cancer	0.000115	0.00166	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SCT—pancreatic cancer	0.000115	0.00101	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HEY1—pancreatic cancer	0.000115	0.00101	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—AGTR1—pancreatic cancer	0.000115	0.001	CbGpPWpGaD
Cysteamine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000114	0.00164	CcSEcCtD
Cysteamine—Skin disorder—Docetaxel—pancreatic cancer	0.000113	0.00163	CcSEcCtD
Cysteamine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000112	0.00161	CcSEcCtD
Cysteamine—Renal failure—Doxorubicin—pancreatic cancer	0.000112	0.00161	CcSEcCtD
Cysteamine—Dizziness—Irinotecan—pancreatic cancer	0.000112	0.0016	CcSEcCtD
Cysteamine—Anorexia—Docetaxel—pancreatic cancer	0.000111	0.0016	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—KRAS—pancreatic cancer	0.000111	0.000967	CbGpPWpGaD
Cysteamine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000111	0.00159	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SCT—pancreatic cancer	0.00011	0.000965	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HEY1—pancreatic cancer	0.00011	0.000965	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCK—pancreatic cancer	0.00011	0.000961	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000109	0.00157	CcSEcCtD
Cysteamine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000109	0.00156	CcSEcCtD
Cysteamine—Urethral disorder—Epirubicin—pancreatic cancer	0.000108	0.00156	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—TNF—pancreatic cancer	0.000107	0.00094	CbGpPWpGaD
Cysteamine—Vomiting—Irinotecan—pancreatic cancer	0.000107	0.00154	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CNR2—pancreatic cancer	0.000107	0.000936	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—GLP1R—pancreatic cancer	0.000107	0.000936	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—CXCL8—pancreatic cancer	0.000107	0.000936	CbGpPWpGaD
Cysteamine—Dizziness—Fluorouracil—pancreatic cancer	0.000107	0.00153	CcSEcCtD
Cysteamine—Rash—Irinotecan—pancreatic cancer	0.000106	0.00153	CcSEcCtD
Cysteamine—Dermatitis—Irinotecan—pancreatic cancer	0.000106	0.00153	CcSEcCtD
Cysteamine—Headache—Irinotecan—pancreatic cancer	0.000106	0.00152	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CCKAR—pancreatic cancer	0.000105	0.000921	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCK—pancreatic cancer	0.000105	0.000921	CbGpPWpGaD
Cysteamine—Vomiting—Gemcitabine—pancreatic cancer	0.000104	0.0015	CcSEcCtD
Cysteamine—Somnolence—Docetaxel—pancreatic cancer	0.000104	0.00149	CcSEcCtD
Cysteamine—Rash—Gemcitabine—pancreatic cancer	0.000104	0.00149	CcSEcCtD
Cysteamine—Dermatitis—Gemcitabine—pancreatic cancer	0.000103	0.00149	CcSEcCtD
Cysteamine—Headache—Gemcitabine—pancreatic cancer	0.000103	0.00148	CcSEcCtD
Cysteamine—Vomiting—Fluorouracil—pancreatic cancer	0.000103	0.00148	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CNR2—pancreatic cancer	0.000103	0.000898	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—GLP1R—pancreatic cancer	0.000103	0.000898	CbGpPWpGaD
Cysteamine—Dyspepsia—Docetaxel—pancreatic cancer	0.000103	0.00147	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—CXCL8—pancreatic cancer	0.000103	0.000897	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—JAG2—pancreatic cancer	0.000102	0.000893	CbGpPWpGaD
Cysteamine—Rash—Fluorouracil—pancreatic cancer	0.000102	0.00146	CcSEcCtD
Cysteamine—Dermatitis—Fluorouracil—pancreatic cancer	0.000102	0.00146	CcSEcCtD
Cysteamine—Decreased appetite—Docetaxel—pancreatic cancer	0.000101	0.00146	CcSEcCtD
Cysteamine—Headache—Fluorouracil—pancreatic cancer	0.000101	0.00145	CcSEcCtD
Cysteamine—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000101	0.00145	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CCKAR—pancreatic cancer	0.000101	0.000883	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000101	0.00145	CcSEcCtD
Cysteamine—SST—Signaling Pathways—MEN1—pancreatic cancer	0.000101	0.00088	CbGpPWpGaD
Cysteamine—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000101	0.00145	CcSEcCtD
Cysteamine—Fatigue—Docetaxel—pancreatic cancer	0.0001	0.00144	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—pancreatic cancer	0.0001	0.00144	CcSEcCtD
Cysteamine—Nausea—Irinotecan—pancreatic cancer	0.0001	0.00144	CcSEcCtD
Cysteamine—Immune system disorder—Epirubicin—pancreatic cancer	0.0001	0.00144	CcSEcCtD
Cysteamine—Constipation—Docetaxel—pancreatic cancer	9.97e-05	0.00143	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—JAG2—pancreatic cancer	9.79e-05	0.000856	CbGpPWpGaD
Cysteamine—Nausea—Gemcitabine—pancreatic cancer	9.76e-05	0.0014	CcSEcCtD
Cysteamine—Mental disorder—Epirubicin—pancreatic cancer	9.7e-05	0.00139	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—MEN1—pancreatic cancer	9.65e-05	0.000844	CbGpPWpGaD
Cysteamine—Erythema—Epirubicin—pancreatic cancer	9.63e-05	0.00138	CcSEcCtD
Cysteamine—Malnutrition—Epirubicin—pancreatic cancer	9.63e-05	0.00138	CcSEcCtD
Cysteamine—Feeling abnormal—Docetaxel—pancreatic cancer	9.61e-05	0.00138	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SHH—pancreatic cancer	9.6e-05	0.00084	CbGpPWpGaD
Cysteamine—Nausea—Fluorouracil—pancreatic cancer	9.59e-05	0.00138	CcSEcCtD
Cysteamine—SST—Signaling Pathways—NOTCH4—pancreatic cancer	9.54e-05	0.000834	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Docetaxel—pancreatic cancer	9.53e-05	0.00137	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IAPP—pancreatic cancer	9.48e-05	0.000829	CbGpPWpGaD
Cysteamine—Tension—Epirubicin—pancreatic cancer	9.45e-05	0.00136	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—HRAS—pancreatic cancer	9.4e-05	0.000822	CbGpPWpGaD
Cysteamine—Nervousness—Epirubicin—pancreatic cancer	9.36e-05	0.00134	CcSEcCtD
Cysteamine—Immune system disorder—Doxorubicin—pancreatic cancer	9.25e-05	0.00133	CcSEcCtD
Cysteamine—Body temperature increased—Docetaxel—pancreatic cancer	9.21e-05	0.00132	CcSEcCtD
Cysteamine—Abdominal pain—Docetaxel—pancreatic cancer	9.21e-05	0.00132	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SHH—pancreatic cancer	9.2e-05	0.000805	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NOTCH4—pancreatic cancer	9.15e-05	0.0008	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTHLH—pancreatic cancer	9.1e-05	0.000796	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTCH1—pancreatic cancer	9.1e-05	0.000796	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IAPP—pancreatic cancer	9.09e-05	0.000795	CbGpPWpGaD
Cysteamine—Mental disorder—Doxorubicin—pancreatic cancer	8.97e-05	0.00129	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—pancreatic cancer	8.91e-05	0.00128	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—pancreatic cancer	8.91e-05	0.00128	CcSEcCtD
Cysteamine—Anaemia—Epirubicin—pancreatic cancer	8.9e-05	0.00128	CcSEcCtD
Cysteamine—Agitation—Epirubicin—pancreatic cancer	8.85e-05	0.00127	CcSEcCtD
Cysteamine—Tension—Doxorubicin—pancreatic cancer	8.75e-05	0.00126	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PTHLH—pancreatic cancer	8.73e-05	0.000763	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PTCH1—pancreatic cancer	8.73e-05	0.000763	CbGpPWpGaD
Cysteamine—Nervousness—Doxorubicin—pancreatic cancer	8.66e-05	0.00124	CcSEcCtD
Cysteamine—Leukopenia—Epirubicin—pancreatic cancer	8.62e-05	0.00124	CcSEcCtD
Cysteamine—Hypersensitivity—Docetaxel—pancreatic cancer	8.59e-05	0.00123	CcSEcCtD
Cysteamine—Asthenia—Docetaxel—pancreatic cancer	8.36e-05	0.0012	CcSEcCtD
Cysteamine—Convulsion—Epirubicin—pancreatic cancer	8.35e-05	0.0012	CcSEcCtD
Cysteamine—Hypertension—Epirubicin—pancreatic cancer	8.32e-05	0.0012	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—pancreatic cancer	8.24e-05	0.00118	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—PIK3CG—pancreatic cancer	8.21e-05	0.000718	CbGpPWpGaD
Cysteamine—Agitation—Doxorubicin—pancreatic cancer	8.19e-05	0.00118	CcSEcCtD
Cysteamine—SST—Signaling Pathways—JAG1—pancreatic cancer	8.15e-05	0.000712	CbGpPWpGaD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	8.15e-05	0.00117	CcSEcCtD
Cysteamine—SST—Signaling Pathways—NOTCH3—pancreatic cancer	8.11e-05	0.000709	CbGpPWpGaD
Cysteamine—Discomfort—Epirubicin—pancreatic cancer	8.1e-05	0.00116	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SST—pancreatic cancer	7.98e-05	0.000698	CbGpPWpGaD
Cysteamine—Leukopenia—Doxorubicin—pancreatic cancer	7.98e-05	0.00115	CcSEcCtD
Cysteamine—Diarrhoea—Docetaxel—pancreatic cancer	7.98e-05	0.00115	CcSEcCtD
Cysteamine—Confusional state—Epirubicin—pancreatic cancer	7.93e-05	0.00114	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.87e-05	0.000688	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Epirubicin—pancreatic cancer	7.86e-05	0.00113	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—JAG1—pancreatic cancer	7.81e-05	0.000683	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NOTCH3—pancreatic cancer	7.78e-05	0.00068	CbGpPWpGaD
Cysteamine—Convulsion—Doxorubicin—pancreatic cancer	7.72e-05	0.00111	CcSEcCtD
Cysteamine—Nervous system disorder—Epirubicin—pancreatic cancer	7.71e-05	0.00111	CcSEcCtD
Cysteamine—Dizziness—Docetaxel—pancreatic cancer	7.71e-05	0.00111	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—pancreatic cancer	7.7e-05	0.00111	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CNR1—pancreatic cancer	7.68e-05	0.000672	CbGpPWpGaD
Cysteamine—Skin disorder—Epirubicin—pancreatic cancer	7.64e-05	0.0011	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	7.54e-05	0.00108	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—pancreatic cancer	7.5e-05	0.00108	CcSEcCtD
Cysteamine—Anorexia—Epirubicin—pancreatic cancer	7.49e-05	0.00108	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—PIK3CG—pancreatic cancer	7.45e-05	0.000652	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—GCG—pancreatic cancer	7.42e-05	0.000649	CbGpPWpGaD
Cysteamine—Vomiting—Docetaxel—pancreatic cancer	7.41e-05	0.00106	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CNR1—pancreatic cancer	7.36e-05	0.000644	CbGpPWpGaD
Cysteamine—Rash—Docetaxel—pancreatic cancer	7.35e-05	0.00106	CcSEcCtD
Cysteamine—Dermatitis—Docetaxel—pancreatic cancer	7.34e-05	0.00106	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—pancreatic cancer	7.34e-05	0.00105	CcSEcCtD
Cysteamine—Headache—Docetaxel—pancreatic cancer	7.3e-05	0.00105	CcSEcCtD
Cysteamine—Anaphylactic shock—Doxorubicin—pancreatic cancer	7.27e-05	0.00105	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.22e-05	0.000631	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CG—pancreatic cancer	7.15e-05	0.000625	CbGpPWpGaD
Cysteamine—Nervous system disorder—Doxorubicin—pancreatic cancer	7.13e-05	0.00103	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—GCG—pancreatic cancer	7.11e-05	0.000622	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AGTR1—pancreatic cancer	7.08e-05	0.000619	CbGpPWpGaD
Cysteamine—Skin disorder—Doxorubicin—pancreatic cancer	7.07e-05	0.00102	CcSEcCtD
Cysteamine—Somnolence—Epirubicin—pancreatic cancer	6.99e-05	0.001	CcSEcCtD
Cysteamine—SST—Signaling Pathways—STK11—pancreatic cancer	6.98e-05	0.00061	CbGpPWpGaD
Cysteamine—Anorexia—Doxorubicin—pancreatic cancer	6.93e-05	0.000996	CcSEcCtD
Cysteamine—Nausea—Docetaxel—pancreatic cancer	6.92e-05	0.000995	CcSEcCtD
Cysteamine—Dyspepsia—Epirubicin—pancreatic cancer	6.92e-05	0.000994	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.92e-05	0.000605	CbGpPWpGaD
Cysteamine—Decreased appetite—Epirubicin—pancreatic cancer	6.83e-05	0.000982	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.79e-05	0.000975	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—AGTR1—pancreatic cancer	6.79e-05	0.000593	CbGpPWpGaD
Cysteamine—Fatigue—Epirubicin—pancreatic cancer	6.78e-05	0.000974	CcSEcCtD
Cysteamine—Constipation—Epirubicin—pancreatic cancer	6.72e-05	0.000966	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—STK11—pancreatic cancer	6.69e-05	0.000585	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CD—pancreatic cancer	6.55e-05	0.000573	CbGpPWpGaD
Cysteamine—Feeling abnormal—Epirubicin—pancreatic cancer	6.48e-05	0.000931	CcSEcCtD
Cysteamine—Somnolence—Doxorubicin—pancreatic cancer	6.47e-05	0.000929	CcSEcCtD
Cysteamine—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.43e-05	0.000924	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—pancreatic cancer	6.4e-05	0.00092	CcSEcCtD
Cysteamine—Decreased appetite—Doxorubicin—pancreatic cancer	6.32e-05	0.000909	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.29e-05	0.00055	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CD—pancreatic cancer	6.28e-05	0.00055	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	6.28e-05	0.000902	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—pancreatic cancer	6.27e-05	0.000901	CcSEcCtD
Cysteamine—Urticaria—Epirubicin—pancreatic cancer	6.25e-05	0.000897	CcSEcCtD
Cysteamine—Constipation—Doxorubicin—pancreatic cancer	6.22e-05	0.000894	CcSEcCtD
Cysteamine—Abdominal pain—Epirubicin—pancreatic cancer	6.22e-05	0.000893	CcSEcCtD
Cysteamine—Body temperature increased—Epirubicin—pancreatic cancer	6.22e-05	0.000893	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SMAD4—pancreatic cancer	6.11e-05	0.000534	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—CXCL8—pancreatic cancer	6.04e-05	0.000529	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.03e-05	0.000528	CbGpPWpGaD
Cysteamine—Feeling abnormal—Doxorubicin—pancreatic cancer	5.99e-05	0.000861	CcSEcCtD
Cysteamine—SST—Signaling Pathways—HES1—pancreatic cancer	5.97e-05	0.000522	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	5.95e-05	0.000855	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SMAD4—pancreatic cancer	5.86e-05	0.000512	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—CXCL8—pancreatic cancer	5.8e-05	0.000507	CbGpPWpGaD
Cysteamine—Hypersensitivity—Epirubicin—pancreatic cancer	5.79e-05	0.000832	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—pancreatic cancer	5.78e-05	0.00083	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—pancreatic cancer	5.75e-05	0.000826	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—pancreatic cancer	5.75e-05	0.000826	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—HES1—pancreatic cancer	5.72e-05	0.0005	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CB—pancreatic cancer	5.71e-05	0.0005	CbGpPWpGaD
Cysteamine—Asthenia—Epirubicin—pancreatic cancer	5.64e-05	0.000811	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CXCL8—pancreatic cancer	5.49e-05	0.00048	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CB—pancreatic cancer	5.48e-05	0.000479	CbGpPWpGaD
Cysteamine—Diarrhoea—Epirubicin—pancreatic cancer	5.38e-05	0.000773	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—pancreatic cancer	5.36e-05	0.00077	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CXCL8—pancreatic cancer	5.26e-05	0.00046	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TERT—pancreatic cancer	5.23e-05	0.000457	CbGpPWpGaD
Cysteamine—Asthenia—Doxorubicin—pancreatic cancer	5.22e-05	0.00075	CcSEcCtD
Cysteamine—Dizziness—Epirubicin—pancreatic cancer	5.2e-05	0.000747	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TERT—pancreatic cancer	5.01e-05	0.000438	CbGpPWpGaD
Cysteamine—Vomiting—Epirubicin—pancreatic cancer	5e-05	0.000718	CcSEcCtD
Cysteamine—SST—Signaling Pathways—HIF1A—pancreatic cancer	5e-05	0.000437	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TSC2—pancreatic cancer	4.99e-05	0.000436	CbGpPWpGaD
Cysteamine—Diarrhoea—Doxorubicin—pancreatic cancer	4.98e-05	0.000715	CcSEcCtD
Cysteamine—Rash—Epirubicin—pancreatic cancer	4.96e-05	0.000712	CcSEcCtD
Cysteamine—Dermatitis—Epirubicin—pancreatic cancer	4.95e-05	0.000712	CcSEcCtD
Cysteamine—Headache—Epirubicin—pancreatic cancer	4.93e-05	0.000708	CcSEcCtD
Cysteamine—SST—Signaling Pathways—APOE—pancreatic cancer	4.88e-05	0.000427	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—pancreatic cancer	4.81e-05	0.000691	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—HIF1A—pancreatic cancer	4.79e-05	0.000419	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TSC2—pancreatic cancer	4.78e-05	0.000418	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KDR—pancreatic cancer	4.78e-05	0.000418	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—APOE—pancreatic cancer	4.68e-05	0.000409	CbGpPWpGaD
Cysteamine—Nausea—Epirubicin—pancreatic cancer	4.67e-05	0.000671	CcSEcCtD
Cysteamine—Vomiting—Doxorubicin—pancreatic cancer	4.63e-05	0.000665	CcSEcCtD
Cysteamine—Rash—Doxorubicin—pancreatic cancer	4.59e-05	0.000659	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—KDR—pancreatic cancer	4.58e-05	0.000401	CbGpPWpGaD
Cysteamine—Dermatitis—Doxorubicin—pancreatic cancer	4.58e-05	0.000658	CcSEcCtD
Cysteamine—Headache—Doxorubicin—pancreatic cancer	4.56e-05	0.000655	CcSEcCtD
Cysteamine—SST—Signaling Pathways—NFKBIA—pancreatic cancer	4.55e-05	0.000398	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—NOTCH1—pancreatic cancer	4.5e-05	0.000394	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CG—pancreatic cancer	4.4e-05	0.000385	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—NRAS—pancreatic cancer	4.4e-05	0.000385	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NFKBIA—pancreatic cancer	4.36e-05	0.000381	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EGF—pancreatic cancer	4.35e-05	0.000381	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—pancreatic cancer	4.32e-05	0.000621	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—NOTCH1—pancreatic cancer	4.32e-05	0.000378	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CG—pancreatic cancer	4.22e-05	0.000369	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—NRAS—pancreatic cancer	4.22e-05	0.000369	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EGF—pancreatic cancer	4.17e-05	0.000365	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—EGFR—pancreatic cancer	4.01e-05	0.000351	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CD—pancreatic cancer	3.87e-05	0.000339	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—EGFR—pancreatic cancer	3.85e-05	0.000336	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.83e-05	0.000335	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—KRAS—pancreatic cancer	3.79e-05	0.000332	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CD—pancreatic cancer	3.71e-05	0.000325	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.68e-05	0.000322	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—KRAS—pancreatic cancer	3.63e-05	0.000318	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CA—pancreatic cancer	3.48e-05	0.000305	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CB—pancreatic cancer	3.37e-05	0.000295	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CA—pancreatic cancer	3.34e-05	0.000292	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CXCL8—pancreatic cancer	3.24e-05	0.000284	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CB—pancreatic cancer	3.24e-05	0.000283	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—HRAS—pancreatic cancer	3.22e-05	0.000282	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—AKT1—pancreatic cancer	3.13e-05	0.000274	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CXCL8—pancreatic cancer	3.11e-05	0.000272	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CASP3—pancreatic cancer	3.1e-05	0.000271	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—HRAS—pancreatic cancer	3.09e-05	0.00027	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCND1—pancreatic cancer	3.02e-05	0.000264	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—AKT1—pancreatic cancer	3e-05	0.000263	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CTNNB1—pancreatic cancer	2.99e-05	0.000262	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CASP3—pancreatic cancer	2.98e-05	0.00026	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MMP9—pancreatic cancer	2.93e-05	0.000257	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTEN—pancreatic cancer	2.92e-05	0.000255	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCND1—pancreatic cancer	2.9e-05	0.000253	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CTNNB1—pancreatic cancer	2.87e-05	0.000251	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—AKT1—pancreatic cancer	2.84e-05	0.000249	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MMP9—pancreatic cancer	2.81e-05	0.000246	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PTEN—pancreatic cancer	2.8e-05	0.000245	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—AKT1—pancreatic cancer	2.73e-05	0.000239	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—SRC—pancreatic cancer	2.7e-05	0.000237	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—VEGFA—pancreatic cancer	2.63e-05	0.00023	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—STAT3—pancreatic cancer	2.61e-05	0.000228	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—NRAS—pancreatic cancer	2.6e-05	0.000228	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SRC—pancreatic cancer	2.59e-05	0.000227	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—VEGFA—pancreatic cancer	2.53e-05	0.000221	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—STAT3—pancreatic cancer	2.5e-05	0.000219	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NRAS—pancreatic cancer	2.49e-05	0.000218	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MYC—pancreatic cancer	2.42e-05	0.000212	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TGFB1—pancreatic cancer	2.42e-05	0.000211	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EGFR—pancreatic cancer	2.37e-05	0.000207	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MYC—pancreatic cancer	2.32e-05	0.000203	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TGFB1—pancreatic cancer	2.32e-05	0.000203	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EGFR—pancreatic cancer	2.27e-05	0.000199	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KRAS—pancreatic cancer	2.24e-05	0.000196	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KRAS—pancreatic cancer	2.15e-05	0.000188	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CA—pancreatic cancer	2.06e-05	0.00018	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—pancreatic cancer	1.99e-05	0.000174	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CA—pancreatic cancer	1.97e-05	0.000173	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—pancreatic cancer	1.91e-05	0.000167	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HRAS—pancreatic cancer	1.9e-05	0.000166	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HRAS—pancreatic cancer	1.82e-05	0.00016	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AKT1—pancreatic cancer	1.68e-05	0.000147	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—AKT1—pancreatic cancer	1.61e-05	0.000141	CbGpPWpGaD
